NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









STRM.BIO

STRM.BIO

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://strm.bio/

Last Round

Series 2

Jan 7, 2026

Total Funding Raised

$18.66M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

STRM.BIO is a biotechnology company that is developing a proprietary extracellular vesicle (EV) platform to deliver gene therapies directly to patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

extracellular vesiclesgene therapy deliverynon-viral deliveryin vivo deliverygenetic medicinebiotech platformdrug deliverygene therapycell therapydelivery vehicleEV deliverybiotech R&Dgenetic payloadtargeted deliverynext-gen therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

STRM.BIO Comps

Public and private peers based on sector, stage, and business model.

STRM.BIO comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

STRM.BIO Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series 2Jan 7, 2026
GrantDec 3, 2025
GrantOct 3, 2023
GrantJul 26, 2022
SeedMar 31, 2021

Key People

Founding team and executive leadership

Michael Luther

Chief Executive Officer And Board Of Directors

Executive Team

Rob Hughes

CFO

Executive Team

David Raiser

Chief Operating Officer

Executive Team

STRM.BIO Investors

Notable investors and investment history

STRM.BIO investors
InvestorRounds
Ascension VenturesSeed
The EngineSeed
NIH RADxGrant
GaingelsSeed
Alix VenturesSeed
Gates FoundationGrant
Breakout VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 3, 2025

    Awarded contract from ARPA-H for non-viral delivery technologies.

  • Dec 1, 2025

    Raised $8M in Series Seed 2 funding.

STRM.BIO Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

STRM.BIO Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about STRM.BIO's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range18
Year Founded2019
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.